SynthesisFrontiers in cardiovascular medicine2025
Efficacy and safety of Dengzhan Shengmai capsule in the treatment of chronic heart failure: a systematic review and meta-analysis.
Synthesis in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dengzhan Shengmai Capsule (DZSMC) is a potential treatment for chronic heart failure (CHF). However, its specific benefits in the treatment of CHF remain unclear. Methods: Related randomized controlled trials were searched in eight databases up to January 28, 2025, and included studies were determined according to the inclusion criteria. Subsequently, the basic characteristics and data from these studies were recorded using Excel 2010. Outcome-related data were subsequently imported into Revman 5.3 for meta-analysis. Results: Fifteen randomized controlled trials with 1606 patients were included in this meta-analysis. The results showed that compared to conventional treatment group, DZSMC combination group significantly improved the clinical effective rate [RR = 1.21, 95% CI (1.16,1.26), Conclusion: DZSMC effectively improves clinical symptoms, cardiac function, and ventricular remodeling in CHF patients, with good safety, making it a potential adjuvant therapy for CHF. However, further research is needed to explore the long-term safety of DZSMC in order to enrich clinical evidence. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024507368, PROSPERO [CRD42024507368].
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.